Directorio

We are doing this study to find the most effective, safe dose of an experimental drug called ficerafusp alfa (BCA101 - the study drug) when it is given in combination with pembrolizumab for people who have metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).

We are doing this study to find out if an experimental drug called pegozafermin (the study drug) is a safe and effective option for people who have compensated liver cirrhosis due to MASH.

We are doing this study to collect data, liquid biopsies (blood and urine), and cancer specimens from women with primary epithelial ovarian, peritoneal, or tubal cancer. We are using this information and these samples to create a biobank that might identify future therapeutic targets and help develop new therapies for these types of cancer.

We are doing this study to test if an experimental medical device called the Bioenthesis® implant (the study device) is a safe and effective option for people who are having surgery to repair a torn rotator cuff. The study device is a bubble gum strip-sized, sponge-like scaffold that is made of real human tissue. The implant has two layers: a soft tissue layer to merge with your tendon, and a hard tissue layer to allow a patient's own stem cells to populate the implant from the bone marrow.

We are doing this study to find the most effective, safe dose of an experimental drug called BHV-1530 (the study drug) for adults who have advanced or metastatic solid tumors.

Collection of samples will allow for increased and more focused research on skin conditions and perhaps eventually lead to the development of improved treatment outcomes.

We are doing this study to learn more about how repeated head impacts and concussions from playing sports can impact the health of Black men after middle age (age 50 and above). We want to find out how these injuries might affect things like lifestyle, mood, brain structure, socioeconomic status, and blood markers of brain disease. We hope this study can help reduce disparities in outcomes and improve the detection and diagnosis of brain health.

We are doing this study to find out if an experimental drug called ruxolitinib is a safe and effection option for preventing graft-versus-host disease when it is given in combination with the drugs tacrolimus and methotrexate before and after a peripheral blood stem cell transplant. We want to know if this study drug combination works better than the standard post-transplant treatment of cyclophosphamide, tacrolimus, and mycophenolate mofetil.